Equities research analysts expect that Aclaris Therapeutics Inc (NASDAQ:ACRS) will report earnings of ($1.25) per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Aclaris Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.26) and the highest estimate coming in at ($1.24). Aclaris Therapeutics reported earnings of ($0.63) per share during the same quarter last year, which would indicate a negative year over year growth rate of 98.4%. The business is expected to report its next quarterly earnings results on Tuesday, November 6th.
On average, analysts expect that Aclaris Therapeutics will report full year earnings of ($4.72) per share for the current fiscal year, with EPS estimates ranging from ($4.91) to ($4.53). For the next year, analysts anticipate that the business will report earnings of ($3.99) per share, with EPS estimates ranging from ($4.05) to ($3.88). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Aclaris Therapeutics.
Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings data on Friday, August 3rd. The biotechnology company reported ($1.01) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.05) by $0.04. Aclaris Therapeutics had a negative return on equity of 49.45% and a negative net margin of 1,584.99%. The company had revenue of $3.68 million for the quarter, compared to the consensus estimate of $2.76 million.
ACRS has been the topic of several recent research reports. BidaskClub raised Aclaris Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, October 13th. Zacks Investment Research raised Aclaris Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a report on Wednesday, August 8th. Cantor Fitzgerald set a $50.00 price objective on Aclaris Therapeutics and gave the company a “buy” rating in a report on Monday, July 9th. Finally, JMP Securities cut their price objective on Aclaris Therapeutics from $47.00 to $34.00 and set a “buy” rating on the stock in a report on Tuesday, October 16th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. Aclaris Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $41.60.
Shares of NASDAQ ACRS traded up $0.12 during mid-day trading on Tuesday, hitting $12.65. 3,496 shares of the stock traded hands, compared to its average volume of 414,517. Aclaris Therapeutics has a twelve month low of $11.00 and a twelve month high of $26.33. The company has a market cap of $387.26 million, a price-to-earnings ratio of -5.05 and a beta of 1.22.
In related news, Director Stephen A. Tullman bought 7,100 shares of the business’s stock in a transaction on Thursday, October 4th. The shares were purchased at an average cost of $14.00 per share, with a total value of $99,400.00. Following the acquisition, the director now owns 177,457 shares of the company’s stock, valued at $2,484,398. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, Director Stephen A. Tullman bought 6,250 shares of the business’s stock in a transaction on Wednesday, August 15th. The shares were bought at an average cost of $15.97 per share, for a total transaction of $99,812.50. Following the completion of the acquisition, the director now directly owns 163,757 shares in the company, valued at approximately $2,615,199.29. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 19,950 shares of company stock worth $298,213. 17.00% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. FMR LLC lifted its holdings in Aclaris Therapeutics by 31.1% during the 2nd quarter. FMR LLC now owns 3,355,785 shares of the biotechnology company’s stock worth $67,015,000 after buying an additional 796,805 shares during the period. BlackRock Inc. lifted its holdings in Aclaris Therapeutics by 9.7% during the 2nd quarter. BlackRock Inc. now owns 2,311,641 shares of the biotechnology company’s stock worth $46,163,000 after buying an additional 204,215 shares during the period. Bank of New York Mellon Corp lifted its holdings in Aclaris Therapeutics by 8.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 423,001 shares of the biotechnology company’s stock worth $8,447,000 after buying an additional 31,339 shares during the period. Rice Hall James & Associates LLC lifted its holdings in Aclaris Therapeutics by 88.5% during the 2nd quarter. Rice Hall James & Associates LLC now owns 399,342 shares of the biotechnology company’s stock worth $7,975,000 after buying an additional 187,545 shares during the period. Finally, Northern Trust Corp lifted its holdings in Aclaris Therapeutics by 1.4% during the 1st quarter. Northern Trust Corp now owns 295,571 shares of the biotechnology company’s stock worth $5,179,000 after buying an additional 4,048 shares during the period. 99.72% of the stock is currently owned by hedge funds and other institutional investors.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.
See Also: What is a closed-end mutual fund (CEF)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.